Liquidia Corporation (LQDA)

NASDAQ • Healthcare

$28.64

+$0.65 (+2.3%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$26.69

Day Range$26.31 - $29.18

Avg. Volume (3M)3.8M

Market Cap$2.5B

P/E Ratio18.2

52 Week Range

$21.94$93.61

Next EarningsIn 29 daysNov 2, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$171.6M100%

Gross Profitminus cost of goods$160.1M93%

Operating Incomeminus R&D and overhead$85.5M50%

Net Incomeminus taxes and the rest$74.7M44%

In plain terms: out of every $100 in revenue, Liquidia Corporation keeps $44 as net profit.

Fundamentals & Financials

Revenue (TTM)

$450.9M

Net Income (TTM)

$138.6M

EPS (TTM)

$1.57

ROA (TTM)

26.56%

Current Ratio

2.31

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-14.0%Q3 2025-$0.49

+91.1%Q4 2025-$0.04

+87.5%Q1 2026$0.15

+52.9%Q2 2026$0.52

-2.4%Q3 2026$0.74

Nov 2

in 29 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -2.4%

Liquidia’s revenue topped consensus in the second fiscal quarter of 2026, reported August 12, 2026, as revenue surged 1842.7% to about $171.7 million, up from $8.8 million a year ago, and came in at $171.7 million versus a $168.5 million estimate (+1.9%, topped). Gross profit was roughly $160.1 million, with gross margin at 93.3%, and the company generated operating cash flow of about $80.2 million during the quarter. Consensus for the next period calls for EPS of $0.88 on revenue of $205.9 million.

Next report — what to expect

Liquidia Corporation (LQDA) reports next on November 2, 2026. Heading into the print, recent results show mixed delivery versus expectations, with the company having beaten EPS in 4 of 8 most recent quarters; traders will be watching for updates tied to the upcoming quarterly release.

View full earnings history

About Liquidia Corporation

Liquidia Corporation develops and commercializes pulmonary hypertension therapies in the healthcare sector, with a focus on pharmaceutical products for the United States market. Listed on the NASDAQ Capital Market as LQDA, Liquidia generated $158.3 million of revenue in FY2025 from a business centered on treprostinil-based treatments.

Name

Liquidia Corporation

CEO

Roger A. Jeffs

Website

www.liquidia.com

Industry

Healthcare

Year Founded

2004

Employees

216

Today's Snapshot

AI-generated

LQDA closed 2.3% higher on heavier trading than usual. Wells Fargo analyst downgraded Liquidia after a court ruling weakened its patent position.

Trading Volume

Above 10d avg 6.1M

8.3M

vs S&P 500 Today

Outperforming Market

+1.54%

Updated: October 2, 2026 at 20:18 UTC

Technical Indicators

2 Buy0 Neutral6 Sell

LQDA reflects pronounced weakness across multiple timeframes, with price well below its short, medium and long moving averages and momentum and MACD firmly negative. ADX shows a meaningful directional trend to the downside and OBV aligns with selling pressure, while ATR is very high, indicating elevated volatility. Although RSI and stochastic register oversold readings and Bollinger indications point to extreme levels, these have not overcome the pervasive moving average and momentum breakdown. Technical takeaway: broad technical deterioration with high volatility and persistent selling pressure supports a strong sell conclusion.

All signals